In our study, apabetalone suppressed KYNU expression while restoring HDAC6 levels, and its combination with the HDAC6 inhibitor tubastatin resulted in a synergistic increase in the cellular stress marker DDIT3 and a more pronounced cytotoxic effect across GBM cell lines. The gene discussed is HDAC6; the disease is glioblastoma.